Navigation Links
Samplify Announces Ultrasound Reference Design
Date:4/26/2010

SAN JOSE, Calif., April 26 /PRNewswire/ -- EMBEDDED SYSTEMS CONFERENCE -- Samplify Systems announced today it is providing ultrasound OEMs with a complete 64-channel ultrasound front-end reference design based on Altera's Cyclone® IV FPGAs and Samplify Systems' SAM1600 ADC and intellectual property (IP).  With low-power, high-performance and continuous-wave Doppler (CWD) processing capabilities, the solution can be used as a common front-end hardware platform for systems ranging from portable, hand-carried ultrasound up to full-featured consoles.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080411/AQF028LOGO )

"Samplify has a proven ultrasound receiver design using their analog front-end SAM1600 ADC," said John Sakamoto, senior director, Application Business Units at Altera.  "This collaboration highlights the combination of Samplify's ADC and Altera's Cyclone IV FPGAs into a development system that allows customers to quickly deliver new products into the marketplace with significant functionality such as 64-channels featuring continuous wave and pulse Doppler modes."

"By providing this complete reference design to OEMs, we can shorten the development time of their analog and digital front-end hardware, and enable them to focus on their core differentiating technologies," said Daniel Kreindler, director of marketing for Medical & Imaging at Samplify Systems. "Altera's Cyclone IV FPGAs are ideal for an ultrasound front-end design based on their low power, hig
'/>"/>

SOURCE Samplify Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Samplify Systems Next-Generation Prism 3.0 Real-Time Compression IP Named Finalist in EDN Magazines 20th Annual Innovation Awards
2. PolyTouch Medical Ltd. Announces the Appointment of Karl A. LeBlanc, MD, MBA, FACS as Medical Advisor
3. Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast
4. pHase Pharmaceuticals Announces New Venture
5. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
6. Dehaier Medical Systems Announces Closing of Initial Public Offering on NASDAQ
7. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
8. Codexis, Inc. Announces Pricing of Initial Public Offering
9. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
10. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
11. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , FRIMLEY, England, December 8 , ... Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on,imatinib 400mg ... Only a Small Number of Patients,Discontinued Due to Adverse Events(1) , ...
... ... , ... - Will Use BrainTrack,s College Campus Data to Enhance Elsevier Evolve,Website Registrations ... technical and,medical information products and services, and BrainTrack,( http://www.braintrack.com ), the widely referenced ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... IDXX ), announced today that its Board of ... additional four million,shares of its common stock under its ... open market or in negotiated transactions.,These shares are in ... 2007, under a previous Board authorization. The timing and,amount ...
... Consumer,Healthcare, a division of Wyeth (NYSE: WYE ... named Executive Vice President, Global Research and,Development (R&D), ... the consumer division,s global R&D organization. In her ... R&D efforts to,effectively bring new products to market ...
... Researchers find chronic worry impairs immune response to cancer-causing ... levels of daily stress could explain why some women ... cervical cancer, a new study suggests. , Scientists ... women, all diagnosed with cervical dysplasia (precancerous cervical lesions), ...
... Precious Medicare Dollars on Trial Lawyers and,Focus on Needy ... Blunt (Mo.) today praised President Bush,s proposal that would ... is clear that without substantial reforms, Medicare will not ... The legislation put,forth by the president is the needed ...
... million in bonuses and incentives, ADA, Mich., Feb. ... $1.072 billion, the fifth consecutive year in which the,company ... from the previous year,s sales of $1.12 billion, which ... affected minimally by actions the company took to,terminate the ...
... media outreach for TRIA, the first hair removal ... to enter U.S. home-based beauty device market, NEW ... Rpr Marketing Communications as its U.S. agency of record ... U.S. home-based beauty,device market., SpectraGenics, Inc. is a ...
Cached Medicine News:Health News:Wyeth Consumer Healthcare Names New Head of Global R&D 2Health News:Daily Stress May Raise Women's Risk of Cervical Cancer 2Health News:Daily Stress May Raise Women's Risk of Cervical Cancer 3Health News:Blunt Praises President's Plan to Save Medicare 2Health News:Quixtar Announces Fifth Consecutive Year of Billion-Dollar Sales 2Health News:Spectragenics Names Rpr Marketing Communications Agency of Record 2
Microforceps : Eckardt End & Side Gripping Forceps...
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Microforceps: Spaid Pic Forceps...
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: